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Abstract
Background: To describe complications associated with Amplatzer septal occluders in a patient
with Marfan syndrome
Case presentation: A nine-year-old boy with Marfan syndrome and a 22 mm atrial septal defect
(ASD) was treated successfully by interventional closure of his ASD by placing a 24 mm Amplatzer
septal occluder. Follow up examinations showed a good result but an increasing enlargement of
aortic root, so the patient was scheduled for operation. Intraoperative findings showed a
perforation of the left atrial roof and the non-coronary sinus by penetration of the occluder device
as well as penetration into the right atrial wall. The occluder was resected, the ASD was closed and
the aortic sinus was reconstructed using a Dacron patch.
Conclusion: We describe the first case of a patient with Marfan syndrome and an interventional
closure of an ASD. Due to alterations of the connective tissue, as it is typical for patients with
Marfan syndrome, the Amplatzer occluder probably perforated adjacent structures more easily as
in non-affected individuals. Amplatzer occluders should be used with caution and follow up
examinations should be performed in short intervals.
Background
Marfan syndrome is a relatively common genetic disorder
with an estimated prevalence of 1: 3,000 to 1:10,000. It is
most often caused by mutations in the FBN1 (Fibrillin)
gene [1,2]. Patients typically present with signs and symp-
toms related to alterations of their connective tissue
including tall stature, recurrent back pain, pectus excava-
tum, dural ectasia, subluxation of the lens, aneurysm of
the aortic root with subsequent aortic regurgitation, and
aneurysms of the ascending, descending, or thoracic aorta
which can result in rupture and death.
Marfan syndrome is an autosomal dominant disorder
with the onset of symptoms occurring in the first decade
of life. Nearly 50 percent of patients have to undergo aor-
tic surgery in their lifetime resulting in reconstruction or
replacement of the aortic root or total of this vessel's parts
[3]. In addition, the occurrence of septal defects in
patients with Marfan syndrome is not common.
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We report a nine-year-old boy with an atrial septal defect
of secundum type (ASD II) and Marfan syndrome fulfill-
ing the Ghent criteria, i.e. aortic root enlargement, mitral
regurgitation and prolaps, pectus excavatum and an ele-
vated arm-span-height-ratio. After informed consent was
obtained from the parents, the ASD was treated success-
fully by interventional closure of the defect with an
Amplatzer occluder at the age of 4 (Figure 1). Native
defect length in TEE was 17 mm. Transcatheter sizing with
a 27 mm Amplatzer sizing-balloon catheter (waisted bal-
loon technique) showed a stretched defect-size of 22 mm.
As the transesophageal echo revealed a small aortic rim
(3–4 mm), but sufficient margins of the defect to the atrial
roof, the caval veins, the coronary sinus and the pulmo-
nary veins, we at this past years chose an oversized
Amplatzer device (24 mm) for implantation. After
implantation, the occluder typically braced from the aor-
tic root. The follow up ultrasound controls revealed a
good result with permanent closure of the septal defect
and the device in loco typico. At this time, the aortic root
was enlarged to a diameter of 24 mm. Over a period of 2
years, growth of the aortic root to 30 mm was recognized.
At this time the diameter exceeded the 95th percentile,
and therefore the patient was scheduled for aortic root
repair.
From the surgeon's point of view, the Amplatzer septal
device had penetrated from the left atrium into the non-
coronary sinus of the aortic root with subsequent aneurys-
matic ballooning (Figure 2a and 2b). Also, a covered per-
foration of the left atrial roof was observed and the right
atrial disk of the occluder had penetrated into the roof of
the right atrium without perforation. The original atrial
septal defect was in a central position with an intact supe-
rior rim. In light of these findings, the closure device was
removed and the septal defect directly closed. Perforated
areas were reconstructed by pericardium and the affected
sinus was replaced by a Dacron patch.
Conclusion
To our knowledge this is the first description of aortic root
perforation by a septal occluder in a patient with Marfan
syndrome. There are only a few cases that report destruc-
tion of aortic segments after placement of closure devices
in patients with patent foramen ovale (PFO), patent duc-
tus arteriosus (PDA) or ASD [4-7]. Perforation is a rare
event, occurring in approximately 0.1% of all cases, indi-
cating closure devices are generally safe. The mechanism
of perforation is not well understood but it might be
related to the absence or presence of the anterosuperior
and posteroinferior rims of the atrial septum where the
closure device is fixed in position [8,9]. Interestingly per-
forations are observed uniquely in the anterosuperior wall
and the adjacent aorta [10].
In patients with an altered connective tissue, the reason
for dislocation of closure devices might be different. Thus
far, we know that the affected protein Fibrillin in Marfan
syndrome, plays a crucial role in maintaining the structure
Overhead view of operating fieldFigure 2
Overhead view of operating field: a: Intraaortic view: 1: 
venous canula; 2: aortic clamp; 3: inside of aortic wall; aster-
isk: penetration defect of the non-coronary sinus. b: Intraa-
trial view: 1: venous canula; 2: aortic clamp; 4: ascending 
aorta; 5: right atrial appendage; asterisk: septal device and 
penetration defect of the left atrial roof.
Lateral fluoroscopy after interventional closure of ASDFigure 1
Lateral fluoroscopy after interventional closure of 
ASD: Contrast media is injected in the IVC showing the 
right atrium. Amplatzer Occluder in position of former ASD 
bracing from aortic root (asterisk). T: transesophageal probe; 
IVC: inferior vena cava; RA: right atrium.Page 2 of 3
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of the connective tissue. With the loss of appropriate
structure and therefore rigidity, artificial devices may
breach and alter the tissue more easily than in non-
affected individuals.
Interventionally applied stents that are used to treat tho-
racic aortic aneurysms in patients with Marfan syndrome
[11] are possibly less harmful. Shear forces on the aortic
wall are reduced significantly and the vessels are protected
from these. Closure devices in septal walls move con-
stantly and may be subjected to greater shearing forces.
This can result, as shown in our patient, in deterioration
of clinical findings, i.e. augmentation of aortic root's
diameter, penetration of adjacent structures, dislocation
of the device and the need for early heart or aortic surgery.
Patients with Marfan disease may be at elevated risk for
penetration of Amplatzer devices. As long as it is not pos-
sible to estimate the individual risk by molecular meth-
ods, and the mechanism of penetration is poorly
understood, in our opinion, the use of septal occluders
should be considered with caution. Even though there are
a number of alternative occluders such as the Helex and
the Sideris Patch, that may be less rigid, reports of their
use in patients with Marfan syndrome are nonexistent.
Complication rate, deterioration, and the need of reoper-
ation may occur at an extended level. Thus follow up
examinations in those patients should be applied in short
intervals. Taking in account these considerations, we
would prefer surgery.
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